LEVOTHYROXINE TREATMENT OF SUBCLINICAL (SH) AND OVERT (OH) HYPOTHYROIDISM IN CHILDREN WITH AUTOIMMUNE HASHIMOTO THYROIDITIS (AHT): A RETROSPECTIVE STUDY IN REGARD WITH TSH AND FREE T4 (FT4) AT DIAGNOSIS

S. LEKA-EMIRI<sup>1</sup>, V. PETROU<sup>1</sup>, C. EVANGELOPOULOU<sup>1</sup>, M. KAFETZI<sup>2</sup>, A. FOTINOU<sup>2</sup>, E. VLACHOPAPADOPOULOU<sup>1</sup>, ST. MICHALACOS<sup>1</sup>

<sup>1</sup> Endocrinology-Growth and Development Division, <sup>2</sup> Biochemistry-Hormonology Department, "P&A KYRIAKOU" Children's Hospital, Athens, Greece

## Objectives

Assess the dose of levothyroxine in relation to TSH and FT4 at diagnosis of AHT in children with SH and OH.

## Methods

Eighty eight children (69 girls) with AHT were devided in regard with TSH and FT4 levels at diagnosis [SH-FT4 >0.9 ng/dl: Group 1: TSH: 4.5-7 mU/l, Group 2: TSH: 7-10 mU/l, Group 3: TSH: >10 mU/l and OH: Group 4: TSH>10 mU/l and FT4 ≤0.9ng/dl]. Mean L-T4 dose was reported in μg/Kg/day at diagnosis and at 2.4 years of follow up. TSH targeted levels under treatment were ≤4 mU/l.

## Results

- Mean age at diagnosis was 9.7 yrs (SD, 2.6). Main characteristics are shown in table 1.
- At diagnosis, FT4 levels were significantly lower only in OH with regard to SH groups.
- Similarly, L-T4 dose in OH was significantly higher as compared to SH groups.
- At 2.4 yrs (SD, 1.2) of treatment all patients were euthyroid and TSH and FT4 levels did not differ significantly between groups.
- L-T4 dose was significantly higher in OH as opposed to group 1 and group 2 but not group 3.

	Group 1	Group2	Group 3	Group 4	*p
	(n=26)	(n=26)	(n=21)	(n=15)	
AT DIAGNOSIS					
Age (yrs)	10.2 (2.2)	10.4 (2.6)	9.2 (2.8)	8.6 (2.9)	
Height z-score	0.68 (1.1)	0.47 (1.2)	0.25 (0.9)	0.48 (0.8)	
BMI z-score	0.83 (0.8)	0.78 (0.9)	0.88 (0.9)	1.04 (1.1)	
TSH (mU/l)	5.6 (0.6)	8.1 (0.9)	16.5 (12.9)	57.7 (46.4)	*
FT4 (ng/dl)	1.23 (0.2)	1.18 (0.1)	1.16 (0.1)	0.8 (0.1)	*
L-T4 (μg/Kg/day)	1.1 (0.35)	1.03 (0.27)	1.38 (0.37)	1.91 (0.9)	*
AT FOLLOW UP (2.4 yrs)					
Age (yrs)	12.3 (1.9)	13.1 (2.5)	11.6 (3.2)	10.7(2.8)	
Height z-score	0.69 (1.0)	0.46 (1.1)	0.43 (0.8	0.76 (0.9)	
BMI z-score	0.65 (0.8)	0.65 (0.8)	0.92 (0.9)	0.89 (0.9)	
TSH (mU/I)	2.5 (1.3)	2.8 (1.3)	2.2 (1.2)	2.1 (0.9)	
FT4 (ng/dl)	1.4 (0.2)	1.3 (0.2)	1.3 (0.2)	1.2 (0.2)	
L-T4 (μg/Kg/day)	1.2 (0.3)	1.2 (0.3)	1.5 (0.4)	1.9 (1.2)	*

Table 1. Data are shown as means (SD). \*One-Way Analysis of variance (ANOVA), p<0.05.

## Conclusions

- At diagnosis, L-T4 needs are significantly lower in SH patients as opposed to OH patients.
- At 2.4 years of therapy, children with OH receive significantly higher LT-4 doses than those with SH and TSH < 10 mU/l but similar with those of SH and TSH > 10 mU/l.

All authors declare no financial or other conflict of interest.

1. Dorr et al., Horm Res Paediatr, 2015; 84: 266-274 2. Pearce et al., Eur Thyroid J, 2013; 2:215-228







